Invention Grant
- Patent Title: Bi-terminal pegylated integrin-binding peptides and methods of use thereof
-
Application No.: US17131324Application Date: 2020-12-22
-
Publication No.: US11485758B2Publication Date: 2022-11-01
- Inventor: Sven H. Hausner , Julie L. Sutcliffe
- Applicant: The Regents of the University of California
- Applicant Address: US CA Oakland
- Assignee: The Regents of the University of California
- Current Assignee: The Regents of the University of California
- Current Assignee Address: US CA Oakland
- Agency: Kilpatrick Townsend & Stockton LLP
- Main IPC: C07K7/06
- IPC: C07K7/06 ; A61K38/00 ; A61K47/60 ; A61K47/64 ; A61K51/08 ; C07K14/705 ; A61K31/337

Abstract:
The present invention provides bi-terminal PEGylated peptide conjugates that target an integrin such as αvβ6 integrin. In particular embodiments, the peptide conjugates of the present invention further comprise a biological agent such as an imaging agent or a therapeutic agent, e.g., covalently attached to one of the PEG moieties. The peptide conjugates of the present invention are particularly useful for imaging a tumor, organ, or tissue and for treating integrin-mediated diseases and disorders such as cancer, inflammatory diseases, autoimmune diseases, chronic fibrosis, chronic obstructive pulmonary disease (COPD), lung emphysema, and chronic wounding skin disease. Compositions and kits containing the peptide conjugates of the present invention find utility in a wide range of applications including, e.g., in vivo imaging and immunotherapy.
Public/Granted literature
- US20210206804A1 BI-TERMINAL PEGYLATED INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF Public/Granted day:2021-07-08
Information query